# A Phase IIII Study of AL8326 in Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06247605/  
OnCo record `nct06247605` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing AL8326 in small-cell lung cancer and non-small-cell lung cancer, now recruiting.

## Summary

A Phase IIII Study of AL8326 in Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06247605, led by Advenchen Laboratories Nanjing, and recruiting on the registry. Official title: Phase III Clinical Study of AL8326 Tablets in Patients With Advanced or Recurrent Small Cell Lung Cancer After at Least Prior Second-line Treatment. Planned enrolment is 243 participants (estimated). The study started in 2023-10-26 and primary completion is expected in 2028-07. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06247605
- Phase: 3
- Setting: Phase III Clinical Study of AL8326 Tablets in Patients With Advanced or Recurrent Small Cell Lung Cancer After at Least Prior Second-line Treatment
- Sponsor: Advenchen Laboratories Nanjing
- Enrolled: 243

## Sources

- ClinicalTrials.gov NCT06247605: https://clinicaltrials.gov/study/NCT06247605

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [AL8326](https://onco.cc/drugs/al8326/)
- companies: [Advenchen Laboratories](https://onco.cc/companies/advenchen-laboratories/)

---
JSON: https://onco.cc/api/v1/entities/nct06247605.json